[go: up one dir, main page]

MX2015007730A - Metodo para obtener una vacuna de mycoplasma. - Google Patents

Metodo para obtener una vacuna de mycoplasma.

Info

Publication number
MX2015007730A
MX2015007730A MX2015007730A MX2015007730A MX2015007730A MX 2015007730 A MX2015007730 A MX 2015007730A MX 2015007730 A MX2015007730 A MX 2015007730A MX 2015007730 A MX2015007730 A MX 2015007730A MX 2015007730 A MX2015007730 A MX 2015007730A
Authority
MX
Mexico
Prior art keywords
subject
immunogenic composition
mycoplasma
making
relates
Prior art date
Application number
MX2015007730A
Other languages
English (en)
Other versions
MX361273B (es
Inventor
Arun V Iyer
Dianna M Murphy Jordan
Brian Thomas Martinson
Christine Margaret Muehlenthaler
Axel Neubauer
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015007730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of MX2015007730A publication Critical patent/MX2015007730A/es
Publication of MX361273B publication Critical patent/MX361273B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere, entre otros, a un método para la preparación de una composición inmunogénica para el tratamiento y/o la profilaxis de infecciones por mycoplasmas en un sujeto, que comprende cultivar bacterias de Mycoplasrna en un sistema de células eucarióticas con una cantidad reducida de suero o libre de suero porcino; obtener un antígeno de las bacterias de Mycoplasma; y agregar un portador aceptable desde el punto de vista farmacéutico. Además, la presente invención se refiere a la composición inmunogénica que se puede obtener mediante dicho método y a un método para inmunizar a un sujeto, que comprende la administración de la composición inmunogénica a un sujeto.
MX2015007730A 2012-12-28 2013-12-20 Metodo para obtener una vacuna de mycoplasma. MX361273B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746997P 2012-12-28 2012-12-28
PCT/US2013/076807 WO2014105672A1 (en) 2012-12-28 2013-12-20 Method of making a mycoplasma vaccine

Publications (2)

Publication Number Publication Date
MX2015007730A true MX2015007730A (es) 2015-09-07
MX361273B MX361273B (es) 2018-12-03

Family

ID=49917778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007730A MX361273B (es) 2012-12-28 2013-12-20 Metodo para obtener una vacuna de mycoplasma.

Country Status (23)

Country Link
US (2) US9273281B2 (es)
EP (1) EP2938747B1 (es)
JP (2) JP6122146B2 (es)
KR (1) KR102153275B1 (es)
CN (2) CN108379571A (es)
AR (1) AR094648A1 (es)
AU (1) AU2013370983B2 (es)
BR (1) BR112015012711B1 (es)
CA (1) CA2896298C (es)
CL (1) CL2015001562A1 (es)
DK (1) DK2938747T3 (es)
EA (1) EA032772B1 (es)
ES (1) ES2738100T3 (es)
HU (1) HUE045015T2 (es)
MX (1) MX361273B (es)
MY (1) MY173223A (es)
PH (1) PH12015501333B1 (es)
PL (1) PL2938747T3 (es)
PT (1) PT2938747T (es)
SG (2) SG11201505089YA (es)
TW (2) TWI660736B (es)
UA (1) UA121193C2 (es)
WO (1) WO2014105672A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
BR112015015199B1 (pt) * 2012-12-28 2022-09-06 Boehringer Ingelheim Vetmedica Gmbh Composição imunogênica compreendendo antígenos de micoplasma e uso
CN108379571A (zh) * 2012-12-28 2018-08-10 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
EP3408281A4 (en) * 2016-01-29 2019-08-14 Advanced Animal Diagnostics, Inc. METHOD AND COMPOSITIONS FOR DETECTING MYCOPLASMA EXPOSURE
RU2724549C1 (ru) * 2016-08-09 2020-06-23 Эгрикалчурал Текнолоджи Рисерч Инститьют Композиция для профилактики и лечения инфекции mycoplasma hyorhinis и способ получения указанной композиции
EP3576799A4 (en) * 2017-02-03 2020-12-30 The Administrators of The Tulane Educational Fund OPHTHALMIC COMPOSITIONS FOR THERAPEUTIC AND PROPHYLACTIC USE
JP6828745B2 (ja) 2017-05-24 2021-02-10 三菱ケミカル株式会社 シートモールディングコンパウンド、繊維強化複合材料および繊維強化複合材料の製造方法
BR112021025021A2 (pt) 2019-06-10 2022-05-03 Elanco Us Inc Formulações de meios de mycoplasma
CN113201050B (zh) * 2020-08-06 2022-07-22 青岛诺安百特生物技术有限公司 一种金黄色葡萄球菌噬菌体穿孔素及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
GB1074920A (en) * 1965-04-21 1967-07-05 Pfizer & Co C Growth medium for mycoplasma pneumoniae and vaccine production
GB1137306A (en) * 1966-07-11 1968-12-18 Research Corp Inoculum for poultry
JPS5540568B2 (es) * 1972-10-05 1980-10-18
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US6825036B2 (en) * 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP3402304B2 (ja) * 2000-03-30 2003-05-06 株式会社微生物化学研究所 猫クラミジアワクチンの製造方法
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
BR0211049A (pt) 2001-07-02 2004-07-20 Pfizer Prod Inc Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
ES2312580T5 (es) 2001-07-02 2017-12-11 Zoetis Services Llc Vacunación en dosis única con l Mycoplasma hyopneumoniae /l
WO2003017755A2 (en) 2001-08-28 2003-03-06 Pfizer Products Inc. Mycoplasma bovis challenge model, methods for administering m.bovis and methods for inducing pneumonic lung lesions
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
US20080185755A1 (en) 2005-02-09 2008-08-07 Todd Deaville Method of Manufacturing a semi-Structural Panel
WO2006095431A1 (ja) * 2005-03-10 2006-09-14 Kyoritsu Seiyaku Corporation 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法
EA200801089A1 (ru) * 2005-10-14 2008-10-30 Иван Петаев Лечение и диагностика облигатных внутриклеточных патогенов
MX2009002741A (es) 2006-09-15 2009-05-11 Medimmune Llc Lineas de celulas mdck que soportan el crecimiento viral para altos titulos y proceso de biorreactor que utiliza las mismas.
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
UA98812C2 (ru) 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
BRPI0907438A2 (pt) 2008-01-23 2015-08-04 Boehringer Ingelheim Vetmed Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
JPWO2009142086A1 (ja) 2008-05-23 2011-09-29 学校法人 久留米大学 マイコプラズマ感染症用ワクチン組成物
LT3056214T (lt) 2008-06-27 2019-06-10 Zoetis Services Llc Naujos adjuvantų kompozicijos
KR20110089260A (ko) 2008-10-31 2011-08-05 베링거잉겔하임베트메디카인코퍼레이티드 다가 백신 조성물에서 마이코플라즈마 보비스 유래의 항원을 포함하는 다양한 항원의 용도
ES2579935T3 (es) 2009-05-19 2016-08-17 Bioproperties Pty Ltd Cepa de vacuna de Mycoplasma Hyopneumoniae sensible a temperatura y uso de la misma
US20110150770A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
US8112663B2 (en) 2010-03-26 2012-02-07 Lsi Corporation Method to establish redundancy and fault tolerance better than RAID level 6 without using parity
CN102258776B (zh) 2011-07-07 2013-07-10 普莱柯生物工程股份有限公司 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
BR112015015199B1 (pt) 2012-12-28 2022-09-06 Boehringer Ingelheim Vetmedica Gmbh Composição imunogênica compreendendo antígenos de micoplasma e uso
CN108379571A (zh) 2012-12-28 2018-08-10 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法

Also Published As

Publication number Publication date
JP2016508983A (ja) 2016-03-24
US20140186394A1 (en) 2014-07-03
TW201832777A (zh) 2018-09-16
MY173223A (en) 2020-01-07
AU2013370983A1 (en) 2015-05-21
CA2896298A1 (en) 2014-07-03
AU2013370983B2 (en) 2019-09-26
EA201500701A1 (ru) 2015-12-30
TWI618542B (zh) 2018-03-21
PH12015501333A1 (en) 2015-09-02
EP2938747B1 (en) 2019-05-01
EA032772B1 (ru) 2019-07-31
JP6449364B2 (ja) 2019-01-09
KR102153275B1 (ko) 2020-09-09
JP6122146B2 (ja) 2017-04-26
PL2938747T3 (pl) 2019-11-29
TW201438732A (zh) 2014-10-16
JP2017145253A (ja) 2017-08-24
KR20150100920A (ko) 2015-09-02
TWI660736B (zh) 2019-06-01
ES2738100T3 (es) 2020-01-20
PT2938747T (pt) 2019-08-01
BR112015012711A2 (pt) 2017-07-11
CN104968365A (zh) 2015-10-07
UA121193C2 (uk) 2020-04-27
DK2938747T3 (da) 2019-08-05
CA2896298C (en) 2024-01-16
EP2938747A1 (en) 2015-11-04
US10512680B2 (en) 2019-12-24
PH12015501333B1 (en) 2022-10-05
CL2015001562A1 (es) 2016-06-24
WO2014105672A1 (en) 2014-07-03
SG11201505089YA (en) 2015-07-30
US20160136254A1 (en) 2016-05-19
SG10201708028VA (en) 2017-10-30
CN104968365B (zh) 2018-04-03
US9273281B2 (en) 2016-03-01
MX361273B (es) 2018-12-03
CN108379571A (zh) 2018-08-10
BR112015012711B1 (pt) 2022-08-16
HUE045015T2 (hu) 2019-11-28
AR094648A1 (es) 2015-08-19

Similar Documents

Publication Publication Date Title
PH12015501333B1 (en) Method of making a mycoplasma vaccine
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
GB201101665D0 (en) Immunogenic compositions
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
PH12013502442A1 (en) Inactivated dengue virus vaccine
EA201300915A1 (ru) Новый европейский штамм prrsv
SG10201804817TA (en) Delayed release compositions of linaclotide
GEP201706668B (en) Parenteral norovirus vaccine formulations
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
IN2013MU00711A (es)
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
EA201491845A1 (ru) Получение стерильных активных фармацевтических ингредиентов
MX363044B (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
IN2011CH03893A (es)
IN2013CH04314A (es)
MX2015007195A (es) Preparacion de vacunas vivas.
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
UA69975U (ru) Способ коррекции показателей клеточного звена иммунитета у больных неалкогольным стеатогепатитом
IN2013MU01944A (es)
IN2013MU02059A (es)

Legal Events

Date Code Title Description
FG Grant or registration